PHARMACOKINETICS (PK) OF PROPYLENE GLYCOL-FREE MELPHALAN HCL (PG-FREE MEL) IN MULTIPLE MYELOMA (MM) PATIENTS UNDERGOING AUTOLOGOUS TRANSPLANTATION (AHCT)

被引：0
|
作者：
Hari, P. [1 ]
Dhakal, B. [1 ]
D'souza, A. [1 ]
Thompson, R. [1 ]
Hamadani, M. [1 ]
Pasquini, M. [1 ]
Chhabra, S. [1 ]
机构：
[1] Med Coll Wisconsin, Milwaukee, WI 53226 USA
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1523
引用
收藏
页码：621 / 621
页数：1
相关论文
共 50 条
  • [31] Bortezomib and Melphalan (Bor/MEL) Conditioning for Patients with Multiple Myeloma Undergoing Single Autologous Stem Cell Transplantation
    Zepeda, Victor H. Jimenez
    Duggan, Peter
    Neri, Paola E.
    Bahlis, Nizar J.
    BLOOD, 2014, 124 (21)
  • [32] A Phase IV, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) As a Myeloablative Conditioning Regimen in Chinese Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
    Wang, Fengrong
    Cai, Zhen
    Zou, Dehui
    Chen, Wenming
    Song, Yongping
    Fu, Chengcheng
    Hu, Jiong
    Yang, Ting
    Chen, Xinchuan
    Yan, Jinsong
    Liu, Kaiyan
    BLOOD, 2022, 140 : 4845 - 4847
  • [33] Population Pharmacokinetics and Bayesian Estimation of Melphalan Concentrations in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
    Mizuno, K.
    Dong, M.
    Fukuda, T.
    Anaissie, E. J.
    Vinks, A. A.
    THERAPEUTIC DRUG MONITORING, 2013, 35 (05) : 708 - 709
  • [34] Pharmacokinetics and Efficacy of Generic Melphalan Is Comparable to Innovator Formulation in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
    Pai, Aswin Anand
    Devasia, Anup J.
    Panetta, John Carl
    Mani, Sathya
    Illangeswaran, Raveen Stephen Stallon
    Mohanan, Ezhilpavai
    Balakrishnan, Balaji
    Kulkarni, Uday
    Fouzia, N. A.
    Korula, Anu
    Abraham, Aby
    Srivastava, Alok
    Mathews, Vikram
    George, Biju
    Balasubramanian, Poonkuzhali
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [35] Pharmacokinetics and Efficacy of Generic Melphalan Is Comparable to Innovator Formulation in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
    Pai, Aswin Anand
    Devasia, Anup J.
    Panetta, John Carl
    Mani, Sathya
    Illangeswaran, Raveen Stephen Stallon
    Mohanan, Ezhilpavai
    Balakrishnan, Balaji
    Lakshmi, Kavitha M.
    Kulkarni, Uday
    Aboobacker, Fouzia N.
    Korula, Anu
    Abraham, Aby
    Srivastava, Alok
    Mathews, Vikram
    George, Biju
    Balasubramanian, Poonkuzhali
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (02): : 130 - +
  • [36] MELPHALAN/PREDNISONE/LENALIDOMIDE (MPR) VERSUS HIGH-DOSE MELPHALAN AND AUTOLOGOUS TRANSPLANTATION (MEL200) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS
    Palumbo, A.
    Cavallo, F.
    Gay, F.
    di Toritto, T.
    Cavalli, M.
    Ben Yehuda, D.
    Finsinger, P.
    Rossi, G.
    Rocci, A.
    Siniscalchi, A.
    Barbarano, L.
    Carella, A.
    Catalano, L.
    Musto, P.
    Cerrato, C.
    Marcatti, M.
    Cavo, M.
    Patriarca, F.
    Genuardi, M.
    Redoglia, V.
    Rossini, F.
    Corradini, P.
    Nagler, A.
    Di Raimondo, F.
    Hardan, I.
    Boccadoro, M.
    HAEMATOLOGICA, 2013, 98 : 96 - 96
  • [37] High Dose BCNU/Melphalan Preparative Regimen Doubles Event Free Survival of Myeloma Patients Undergoing Autologous Transplantation
    Gasparetto, Cristina
    Bacon, Wendi A.
    Doan, Phuong
    Rizzieri, David A.
    Horwitz, Mitchell E.
    Chute, John P.
    Sullivan, Keith M.
    Yopp, Amanda
    Li, Zhiguo
    Chao, Nelson J.
    Long, Gwynn D.
    BLOOD, 2011, 118 (21) : 879 - 879
  • [38] Full dose or reduced dose Melphalan (MEL) for autologous stem cell transplantation (ASCT) in multiple myeloma (MM): a single center analysis on 146 patients
    vom Hofe, F.
    Muegge, L-O
    Scholl, S.
    Hilgendorf, I
    Sayer, H.
    Yomade, O.
    Ernst, T.
    Hochhaus, A.
    von Lilienfeld-Toal, M.
    Brioli, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 184 - 184
  • [39] Changes in pulmonary function test (PFT) following high dose cyclophosphamide and melphalan in multiple myeloma (MM) patients undergoing autologous transplantation (AT).
    Jazieh, AR
    Bracy, D
    Spinks, C
    Siegel, D
    Desikan, KR
    Jagannath, S
    Hiller, FC
    Barlogie, B
    Tricot, G
    BLOOD, 1996, 88 (10) : 3752 - 3752
  • [40] Escalating doses of intravenous Busulfan (Bu) with a fixed dose of melphalan (Mel) as a preparative regimen for patients (pts) with multiple myeloma (MM) undergoing autologous peripheral blood stem cell transplantation (PBSCT).
    Callander, NS
    Freytes, CO
    Walsh, T
    Ochoa, L
    Tran, H
    Nguyen, J
    Primeaux, S
    BLOOD, 2003, 102 (11) : 703A - 703A
12345